---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-097777"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:32:14.151828+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BiomX Q3 net income $9.6M on warrant revaluation; DFO Phase 2 enrollment complete, CF topline pushed to H1 2026

## Summary
- Cash $24.7M as of Sep 30, 2024; company expects runway into Q4 2025.
- R&D expenses $7.3M (+30% YoY); G&A $3.2M (+45% YoY); $801K goodwill impairment.
- Net income $9.6M vs net loss $7.9M in Q3 2023 due to warrant fair value change.
- BX211 DFO Phase 2 patient enrollment done; topline results expected Q1 2025.
- BX004 CF Phase 2b topline delayed to H1 2026; manufacturing delays resolved.

## SEC filing metadata
- accession: 0001213900-24-097777
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390024097777/0001213900-24-097777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390024097777/ea0221192-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-097777
- JSON: https://secwatch.observer/filing/0001213900-24-097777.json
- Plain text: https://secwatch.observer/filing/0001213900-24-097777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.